Quick verdict
Eden is the better pick for most patients on overall scoring. Eden is the highest-volume compounded-only brand outside Henry. Slick funnel, low intro pricing, lots of upsell. Quality of clinical experience is thinner than Henry or Ivim and cancellation is the most common complaint thread.
That said, Found wins on specific dimensions. Found has the broadest medication catalog of any program here, including off-label tirzepatide and orforglipron access through their Foundayo program. The 6-month non-refundable subscription is the catch.
Side-by-side
| Found | Eden | |
|---|---|---|
| Starts from | $99/mo (+ med separate) | $179/mo (incl. medication) |
| Lock-in | 6-month lock-in | 3-month minimum |
| Time to prescription | 5 days | 2 days |
| Consultation type | Asynchronous | Asynchronous |
| Affiliate network | Impact | Impact |
Score by dimension
Five dimensions, ten points each. The winner of each dimension is highlighted.
| Found | Eden | |
|---|---|---|
| Pricing transparency | 6/10 | 7/10 |
| Cancellation terms | 3/10 | 5/10 |
| Onboarding experience | 8/10 | 8/10 |
| Medication options | 9/10 | 5/10 |
| Member outcomes | 5/10 | 6/10 |
When to choose Found
Patients whose obesity medicine clinician has flagged a non-standard medication path (multiple drug classes, off-label combinations, or 503A-compounded options that other programs have exited).
When to choose Eden
Price-led buyers willing to navigate a heavier upsell flow for an aggressive intro price.
FAQ
Is Found cheaper than Eden?
Can I switch from Found to Eden mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart →